MAPK8 and hepatocellular carcinoma: Since activation of JNK has been observed in HCC mouse models and HCC patients [9], [10], [12], five HBV transgenic mice and seven non-transgenic control mice at two years of age were carefully identified by genotyping and chosen to study the activation of JNK in the liver.